MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's

Feb. 22, 2023

NRG Therapeutics Ltd. has been awarded a second US$500,000 grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF), to support its lead drug discovery program and the development of a novel treatment for Parkinson's disease.

BioWorld Science Neurology/Psychiatric Grant

Today's news in brief

BioWorld

BioWorld briefs for May 31, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 31, 2023.

FDA approved icons and medical professional

Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

BioWorld

Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...

Gene therapy to reverse T2D shows proof of concept at ASGCT

BioWorld

The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...

Medtronic, Philips, Edwards late-breaking study data spotlighted at EuroPCR

BioWorld MedTech

Among the many companies presenting data at the EuroPCR conference in Paris, several late breaking trials from heavy hitters Medtronic plc, Royal Phillips NV and...

Upgrade your daily dose of biopharma and medtech news

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's